Literature DB >> 24882876

Operative and Conservative Treatment of Uterine Sarcomas.

P Harter1, K El-Khalfaoui1, F Heitz1, A du Bois1.   

Abstract

Uterine sarcomas are rare, aggressive mesenchymal tumours with a relatively poor prognosis. The term comprises various histological subtypes, such as leiomyosarcoma, endometrial stromal sarcomas as well as undifferentiated uterine sarcomas, which require different operative and systemic/radiation therapy strategies accordingly. The evidence on operative, adjuvant and palliative treatment currently available is presented here.

Entities:  

Keywords:  leiomyosarcoma; uterine carcinoma; uterus

Year:  2014        PMID： 24882876      PMCID： PMC4024613          DOI： 10.1055/s-0034-1368204

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN： 0016-5751            Impact factor:   2.915


  25 in total

1.  Uterine leiomyosarcoma: analysis of treatment failures and survival.

Authors:  A Gadducci; F Landoni; E Sartori; P Zola; T Maggino; A Lissoni; L Bazzurini; R Arisio; C Romagnolo; R Cristofani
Journal:  Gynecol Oncol       Date:  1996-07       Impact factor: 5.482

2.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Winette T A van der Graaf; Jean-Yves Blay; Sant P Chawla; Dong-Wan Kim; Binh Bui-Nguyen; Paolo G Casali; Patrick Schöffski; Massimo Aglietta; Arthur P Staddon; Yasuo Beppu; Axel Le Cesne; Hans Gelderblom; Ian R Judson; Nobuhito Araki; Monia Ouali; Sandrine Marreaud; Rachel Hodge; Mohammed R Dewji; Corneel Coens; George D Demetri; Christopher D Fletcher; Angelo Paolo Dei Tos; Peter Hohenberger
Journal:  Lancet       Date:  2012-05-16       Impact factor: 79.321

3.  The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma.

Authors:  Jeong-Yeol Park; Sun-Kyung Park; Dae-Yeon Kim; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  Gynecol Oncol       Date:  2011-05-12       Impact factor: 5.482

Review 4.  Endometrial cancer.

Authors:  Frederic Amant; Philippe Moerman; Patrick Neven; Dirk Timmerman; Erik Van Limbergen; Ignace Vergote
Journal:  Lancet       Date:  2005 Aug 6-12       Impact factor: 79.321

5.  Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.

Authors:  Xavier García-Del-Muro; Antonio López-Pousa; Joan Maurel; Javier Martín; Javier Martínez-Trufero; Antonio Casado; Auxiliadora Gómez-España; Joaquín Fra; Josefina Cruz; Andrés Poveda; Andrés Meana; Carlos Pericay; Ricardo Cubedo; Jordi Rubió; Ana De Juan; Nuria Laínez; Juan Antonio Carrasco; Raquel de Andrés; José M Buesa
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

6.  Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).

Authors:  Martee L Hensley; J Kyle Wathen; Robert G Maki; Dejka M Araujo; Gregory Sutton; Dennis A Priebat; Suzanne George; Robert A Soslow; Laurence H Baker
Journal:  Cancer       Date:  2013-01-18       Impact factor: 6.860

7.  Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.

Authors:  George D Demetri; Sant P Chawla; Margaret von Mehren; Paul Ritch; Laurence H Baker; Jean Y Blay; Kenneth R Hande; Mary L Keohan; Brian L Samuels; Scott Schuetze; Claudia Lebedinsky; Yusri A Elsayed; Miguel A Izquierdo; Javier Gómez; Youn C Park; Axel Le Cesne
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

Review 8.  The management of patients with uterine sarcoma: a debated clinical challenge.

Authors:  Angiolo Gadducci; Stefania Cosio; Antonella Romanini; Andrea Riccardo Genazzani
Journal:  Crit Rev Oncol Hematol       Date:  2007-08-13       Impact factor: 6.312

9.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

Authors:  Robert G Maki; J Kyle Wathen; Shreyaskumar R Patel; Dennis A Priebat; Scott H Okuno; Brian Samuels; Michael Fanucchi; David C Harmon; Scott M Schuetze; Denise Reinke; Peter F Thall; Robert S Benjamin; Laurence H Baker; Martee L Hensley
Journal:  J Clin Oncol       Date:  2007-07-01       Impact factor: 44.544

10.  Low grade endometrial stromal sarcoma of uterine corpus, a clinico-pathological and survey study in 14 cases.

Authors:  Tahereh Ashraf-Ganjoei; Nadereh Behtash; Mamak Shariat; Asamosadat Mosavi
Journal:  World J Surg Oncol       Date:  2006-08-09       Impact factor: 2.754
View more
  2 in total

1.  Surgical Methods for the Treatment of Uterine Fibroids - Risk of Uterine Sarcoma and Problems of Morcellation: Position Paper of the DGGG.

Authors:  M W Beckmann; I Juhasz-Böss; D Denschlag; P Gaß; T Dimpfl; P Harter; P Mallmann; S P Renner; S Rimbach; I Runnebaum; M Untch; S Y Brucker; D Wallwiener
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-02       Impact factor: 2.915

2.  Leiomyosarcoma of the stomach with metastasis to the liver: a case report with review of the literature.

Authors:  Varshil Mehta; Monali Rajawat; Sameer Rastogi; Ravi H Phulware; Roman Mezencev
Journal:  Future Sci OA       Date:  2017-11-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.